M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study

Not Applicable

Completed

Conditions: Solid Tumors
Pain

Interventions: Other: Acupuncture
Behavioral: Survey

First Posted Date: 2007-06-18

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00487331

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Ovarian Cancer Patient Questionnaire on Genetic Testing

Completed

Conditions: Ovarian Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-06-15

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 237

Registration Number: NCT00486707

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Squamous Cell Cancer

Interventions: Drug: Imatinib Mesylate
Drug: Docetaxel

First Posted Date: 2007-06-13

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00485485

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: 2-CdA
Drug: Ara-C
Drug: G-CSF (Granulocyte colony-stimulating factor)

First Posted Date: 2007-06-06

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00483067

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

Phase 3

Completed

Conditions: Radiation Dermatitis

Interventions: Other: RadiaPlexRx Gel
Other: Aquaphor Gel

First Posted Date: 2007-06-04

Last Posted Date: 2016-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00481884

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia
Leukemia

Interventions: Drug: Oxaliplatin
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2007-06-01

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00480987

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Health and Cancer Issues in the South Asian Community

Completed

Conditions: Attitude to Health

Interventions: Behavioral: Focus Groups
Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2007-05-28

Last Posted Date: 2016-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00479830

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Completed

Conditions: Breast Cancer

Interventions: Procedure: Phlebotomy

First Posted Date: 2007-05-25

Last Posted Date: 2017-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 102

Registration Number: NCT00478686

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor
Urethral Cancer

Interventions: Drug: Bortezomib
Drug: Gemcitabine
Drug: Doxorubicin

First Posted Date: 2007-05-25

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00479128

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Docetaxel
Drug: ZD1839
Drug: Dexamethasone

First Posted Date: 2007-05-25

Last Posted Date: 2015-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00479089

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy